Natera, Inc. announced that on September 23, 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay. This assay had previously been preliminarily enjoined in December 2023, marking a significant legal victory for Natera.
The permanent injunction restricts NeoGenomics from offering its previous RaDaR assay, which directly competes with Natera's molecular residual disease (MRD) tests. This development helps to protect Natera's market position and intellectual property in the rapidly evolving field of cell-free DNA diagnostics.
Natera continues to pursue its claims against a modified version of NeoGenomics’ RaDaR for infringement of Natera’s ‘454 patent. The Patent Office's denial of NeoGenomics’ petition to challenge the validity of the ‘454 patent further strengthens Natera's intellectual property defense.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.